Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 94 of 110 Updated Nov 17, 2026

CJC-1295 + Ipamorelin

Mod GRF(1-29) + Ipamorelin · CJC no-DAC + Ipa · GHRH+GHRP blend

ANECDOTAL + ANIMAL STUDIES · GHRH ANALOG + SELECTIVE GHRP BLEND (GH-SECRETAGOGUE STACK)

▓ 5 indexed citations across EuropePMC (5).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

5 citations across 1 tier

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).

Researched effects

Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off

Known concerns

Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Top-ranked picks

5 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

    2026 — RESEARCH ARTICLES · AUTHORITY 34.5

  2. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

    2026 — RESEARCH ARTICLES · AUTHORITY 34.5

  3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    2026 — RESEARCH ARTICLES · AUTHORITY 34.5

  4. Injuries, Injections, and Internet Forums: A Qualitative Study of Reddit User Perspectives on Peptide Therapy After Orthopaedic Surgery.

    2026 — RESEARCH ARTICLES · AUTHORITY 34.5

  5. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    2026 — RESEARCH ARTICLES · AUTHORITY 34.5

Full citation library

Year distribution

Research Articles

5
  1. 1.

    Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ. · 2026 · PMID 42160466

    <h4>Background</h4>Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.<h4>Purpose</h4>To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outc…

  2. 2.

    Mavrych V, Shypilova I, Bolgova O. · 2026 · PMID 42021992

    <h4>Background</h4>Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.<h4>Objective</h4>To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.<h4>Methods</h4>A comprehensiv…

  3. 3.

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · 2026 · PMID 41476424

    <h4>Background</h4>Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.<h4…

  4. 4.

    Rosenberg AE, Taylor B, Rasquinha RD, Khan H, Quinn M, Marcaccio S, Lemme N. · 2026 · PMID 41877514

  5. 5.

    Rahman OF, Lee SJ, Seeds WA. · 2026 · PMID 41490200

    Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodel…

Curated sources on file

3
  1. 1.
  2. 2.
  3. 3.

Continue reading